IRIS
CANTONETTI, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 31.825
EU - Europa 2.905
AS - Asia 1.703
SA - Sud America 103
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 5
Totale 36.565
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.699
DE - Germania 799
SG - Singapore 735
CN - Cina 517
UA - Ucraina 424
IT - Italia 407
IE - Irlanda 337
HK - Hong Kong 237
GB - Regno Unito 233
RU - Federazione Russa 219
FR - Francia 142
CA - Canada 120
KR - Corea 118
FI - Finlandia 103
SE - Svezia 89
BR - Brasile 82
PL - Polonia 44
BE - Belgio 28
AT - Austria 20
NL - Olanda 20
CZ - Repubblica Ceca 12
JP - Giappone 11
EU - Europa 10
ID - Indonesia 10
IN - India 9
CH - Svizzera 8
RO - Romania 8
VN - Vietnam 7
IQ - Iraq 6
MX - Messico 6
AR - Argentina 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
BD - Bangladesh 4
IL - Israele 4
KG - Kirghizistan 4
PH - Filippine 4
PK - Pakistan 4
TR - Turchia 4
BG - Bulgaria 3
CL - Cile 3
UY - Uruguay 3
VE - Venezuela 3
AM - Armenia 2
CO - Colombia 2
EC - Ecuador 2
EG - Egitto 2
GR - Grecia 2
HR - Croazia 2
IR - Iran 2
LA - Repubblica Popolare Democratica del Laos 2
MA - Marocco 2
NO - Norvegia 2
PE - Perù 2
SA - Arabia Saudita 2
TG - Togo 2
TH - Thailandia 2
TW - Taiwan 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CM - Camerun 1
DZ - Algeria 1
EE - Estonia 1
ES - Italia 1
GE - Georgia 1
JO - Giordania 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
MY - Malesia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PY - Paraguay 1
RS - Serbia 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 36.565
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.266
Wilmington 8.715
Houston 7.669
Ann Arbor 810
Fairfield 769
Chandler 585
Singapore 569
Ashburn 440
Jacksonville 389
Seattle 331
Dublin 323
New York 291
Cambridge 279
Medford 237
Hong Kong 235
Beijing 222
Dearborn 198
Rome 152
Munich 137
Santa Clara 126
Lawrence 114
Mcallen 111
Montréal 110
Zhengzhou 72
Mülheim 68
Moscow 55
Menlo Park 52
Milan 43
San Diego 42
Kraków 40
Hefei 33
The Dalles 31
Shanghai 29
Nuremberg 26
Guangzhou 25
University Park 23
Brussels 21
Council Bluffs 21
Norwalk 21
Mountain View 20
Saint Petersburg 20
London 19
Nanjing 19
Helsinki 17
Creede 16
Redwood City 16
Palo Alto 14
Seoul 14
Falls Church 13
Kunming 13
Center 12
Los Angeles 12
Boardman 11
Brno 11
Engelhard 11
North Bergen 11
Nürnberg 11
Frankfurt am Main 10
Jakarta 10
São Paulo 10
Verona 10
Bologna 9
Hebei 7
Nanchang 7
Toronto 7
Wuhan 7
Cedarhurst 6
Chicago 6
Detroit 6
Fuzhou 6
Hangzhou 6
Naples 6
Redmond 6
Vienna 6
Changsha 5
Chengdu 5
Hanoi 5
Kilburn 5
Palermo 5
Phoenix 5
San Jose 5
Shenyang 5
Amsterdam 4
Chongqing 4
Duncan 4
Fremont 4
Manitou Springs 4
Nancy 4
San Mateo 4
Baghdad 3
Bari 3
Chaoyang 3
Chiswick 3
Contagem 3
Manila 3
Monterotondo 3
Montevideo 3
Padova 3
Picinisco 3
Rio de Janeiro 3
Totale 33.166
Salva come PNG Salva come JPEG
Nome #
Awake thoracoscopic biopsy of anterior mediastinal masses 841
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 503
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 483
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 477
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 451
Treatment of multiple myeloma: A randomized study of three different regimens 448
Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol 448
Non-Hodgkin lymphomas of the central nervous system 434
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 429
Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients 427
Comprehensive analysis of PTEN status in Sezary syndrome 427
WILL MOLECULAR-BIOLOGY CONTRIBUTE TO REFINE PROGNOSIS AND TO SELECT TREATMENT 424
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 422
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 418
Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study 415
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 413
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients 413
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion 410
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 410
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial 409
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses 409
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 407
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 407
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 402
Multiple skin tumors in long-term treatment with hydroxyurea 402
Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma 402
Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? 400
FISH analysis for CML monitoring? 399
Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease 397
SEQUENTIAL THERAPY WITH VAPLD AND BORTEZOMIB AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSION BEFORE STEM CELL MOBILIZATION 397
Peripheral polyneuropathy during treatment with alpha-2 interferon 396
Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients 389
Menstrual function in patients undergoing chemotherapy for Hodgkin's disease 385
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group 384
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions. 383
Biological and clinical advances in multiple myeloma: A review 383
Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy 381
TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE 381
Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia 375
Reduced intensity allogeneic transplantation in primary cutaneous t-cell lymphomas. 375
EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986 374
CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE 374
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: An update 373
Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma 372
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 371
PROGNOSTIC VALUE OF CEREBROSPINAL FLUID FLOW CYTOMETRY ANALYSIS IN AGGRESSIVE NHL PATIENTS AT HIGH RISK FOR LEPTOMENINGEAL DISEASE: FCM plus MAY PREDICT AN HIGH RISK OF CNS RELAPSE 371
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 371
Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia 370
Psoriasiform sarcoidosis: an unusual variety 370
INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA 367
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions 367
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients 364
Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment 364
KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML 364
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 363
Monitoring treatment and survbival in Cronic Myeloid Leukemia 361
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial 360
Intermediate stage Hodgkin's disease: Preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy 360
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 359
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias 358
EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY 356
Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis 355
CLIPI: A new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 353
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma 347
Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease 347
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 347
Allogeneic stem cell transplantation for patients with advanced primary cutaneous T-cell lymphoma 343
Chemotherapy in cutaneous T-cell lymphoma 341
Bone marrow processing with a gravity sedimentation technique: experience of 13 cases 341
Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients 339
Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study 338
Surgical management of rhinosinusitis in onco-hematological patients 337
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients 333
Reduced-intensity conditioning combined with standard GvHD prophylaxis is tolerable and highly effective for patients with primary cutaneous T-cell lymphomas undergoing allogeneic transplantation in advanced disease stage. 332
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 332
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 330
PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION 327
Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymph 318
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma 317
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 312
Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. 312
Initial staging of hodgkin's disease: Role of contrast-enhanced 18F FDG PET/CT 306
Il trattamento chirurgico delle rinosinusiti nei pazienti oncoematologici: confronto tra procedure 305
Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs 304
Early detection of IgH monoclonal rearrangenent in follicular spicules of the nose preceding multiple myeloma diagnosis. Case report and review of the literature 304
Granulomatous mycosis fungoides responsive to gemcitabine 293
[Current aspects of treatment of multiple myeloma] 288
Molecular expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinases in plasmacellular disorders: A molecular panel to nvestigate disease progression 247
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 188
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations 166
Recurrent Sweet's syndrome in a patient with multiple myeloma 163
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 158
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 155
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 154
Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients 150
Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry? 144
Nephelometric assay of urine free light chains: An alternative and early clinical test for Bence-Jones protein quantification 144
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant 144
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion 142
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles: Long-term results of the GITIL/FIL HD 0607 trial 139
Totale 35.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.836
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.836
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.408 0 0 0 0 0 0 0 0 0 934 722 752
2020/20215.987 646 713 665 723 633 670 721 581 143 153 284 55
2021/20221.054 43 107 20 76 30 99 44 42 76 87 55 375
2022/20231.592 167 150 77 160 131 349 189 79 137 10 114 29
2023/2024749 52 20 61 20 39 302 33 31 20 13 25 133
2024/20251.875 94 568 302 145 43 141 213 137 203 29 0 0
Totale 36.877